WO2009018373A2 - Administration transdermique de (2s)-(4e)-n-méthyl-5-(3-(5-isopropoxypyridin)yl)-4-pentén-2-amine - Google Patents

Administration transdermique de (2s)-(4e)-n-méthyl-5-(3-(5-isopropoxypyridin)yl)-4-pentén-2-amine Download PDF

Info

Publication number
WO2009018373A2
WO2009018373A2 PCT/US2008/071638 US2008071638W WO2009018373A2 WO 2009018373 A2 WO2009018373 A2 WO 2009018373A2 US 2008071638 W US2008071638 W US 2008071638W WO 2009018373 A2 WO2009018373 A2 WO 2009018373A2
Authority
WO
WIPO (PCT)
Prior art keywords
pain
composition
penten
amine
methyl
Prior art date
Application number
PCT/US2008/071638
Other languages
English (en)
Other versions
WO2009018373A3 (fr
Inventor
Merouane Bencherif
John W. James
Ph.D. Michael G. Williams
Johannes Antonius Maria Neelissen
Original Assignee
Targacept, Inc.
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept, Inc., Astrazeneca Ab filed Critical Targacept, Inc.
Priority to CA2695214A priority Critical patent/CA2695214A1/fr
Priority to BRPI0815070A priority patent/BRPI0815070A2/pt
Priority to US12/671,232 priority patent/US20100247617A1/en
Priority to JP2010520158A priority patent/JP2010535237A/ja
Priority to EP08796889A priority patent/EP2182932A2/fr
Priority to CN200880101391A priority patent/CN101772343A/zh
Priority to NZ582826A priority patent/NZ582826A/en
Priority to AU2008282205A priority patent/AU2008282205A1/en
Publication of WO2009018373A2 publication Critical patent/WO2009018373A2/fr
Publication of WO2009018373A3 publication Critical patent/WO2009018373A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention generally relates to the transdermal administration of (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, or pharmaceutically acceptable salts thereof.
  • metanicotine analogs have been proposed for use in treating a variety of disorders, predominantly via oral administration. See, for example, U.S. Patent No. 5,616,716, U.S. Patent No. 5,861 ,423, U.S. Patent No. 6,232,316 and U.S. Patent 6,958,399, the contents of which are hereby incorporated by reference.
  • some of these compounds suffer from relatively fast degradation in vivo, which makes it difficult to administer them to the site of action via routes that involve first pass metabolism in the liver.
  • routes of administration other than the oral route can be advantageous, particularly if they provide improvements in therapeutic levels or the onset of activity.
  • compositions and methods for administering certain metanicotine analogs It would be advantageous to provide new compositions and methods for administering certain metanicotine analogs.
  • the present invention provides such compositions and methods.
  • the present invention relates the transdermal delivery of 5-(3-(5- isopropoxypyridin)yl)-4-penten-2-amine, and pharmaceutically acceptable salts thereof (hereinafter referred to as active ingredient).
  • (2S)-(4E)-N-methyl-5-(3-(5- isopropoxypyridin)yl)-4-penten-2-amine has acceptable bioavailability when administered orally, but transdermal administration provides other advantages over oral administration.
  • the transdermal drug delivery is carried out using devices that include a polymeric barrier, adhered to the skin with a suitable adhesive, and which also include a suitable amount of the active ingredients, or salts thereof, in solution or dispersion and in contact with the skin or a rate-controlling membrane may be used between the active-containing composition and the skin.
  • the delivery is carried out using semisolid compositions, such as cremes or lotions, which include the active ingredients, and which are applied to the skin.
  • the active ingredients are delivered using iontophoresis, wherein the positively charged active agents are administered by electroosmosis.
  • the active ingredient(s) is formulated within the matrix of the adhesive.
  • the drug delivery devices and/or semi-solid dosage forms can provide instantaneous release, sustained release, or combinations thereof, and can include permeation enhancers and other components to assist in drug transport into the dermis (via transport across the stratum corneum of the epidermis) wherein the active ingredient is available for systemic absorption or local effects.
  • transdermal delivery of (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)- 4-penten-2-amine, or its pharmaceutically acceptable salts can be used to treat and/or prevent any indication which the active ingredient is capable of treating and/or preventing, while delivering the active ingredient in an efficacious manner.
  • Some embodiments relate to methods involve treating or preventing central nervous system disorders.
  • Central nervous system disorders include disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release.
  • the central nervous system (CNS) disorders can be characterized by an alteration in normal neurotransmitter release.
  • Other methods involve treating certain other conditions (e.g., alleviating pain and inflammation).
  • the methods involve administering to a subject an effective amount of a composition as described herein via a transdermal route to treat or prevent the disorder, or to alleviate or eliminate the pain and/or inflammation.
  • the transdermal compositions can also be used in smoking cessation, ideally without the side effect profiles associated with nicotine patches.
  • the compositions can also be used to treat other addictions, such as addiction to alcohol, narcotics (including opiates such as oxycodone, morphine, heroine, and the like), prescription drugs, gambling, and the like.
  • compositions for transdermal administration include an effective amount of (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine or its pharmaceutically acceptable salts, along with pharmaceutically acceptable carriers and/or excipients.
  • the compositions can be in the form of patches containing the active ingredient, or a pharmaceutically acceptable salt thereof.
  • the compositions can optionally include components such as permeation enhancers, adhesives, and means for providing instantaneous and/or sustained release of the active ingredients.
  • the compositions may or may not include a rate-controlling membrane to modulate the release of the active ingredient from the device to the skin.
  • compositions include effective amounts of (2S)-(4E)-N- methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, or its pharmaceutically acceptable salts. Accordingly, the compound is released from the composition, absorbed, and interacts with relevant nicotinic receptor sites of a subject to act as a therapeutic agent for treating or preventing a wide variety of conditions and disorders, particularly central nervous system disorders, (including those disorders characterized by an alteration in normal neurotransmitter release), pain, and/or inflammation.
  • compositions provide therapeutic benefit to individuals suffering from such disorders and exhibiting clinical manifestations of such disorders in that the active ingredients within those compositions, when employed in effective amounts, have the potential to (i) exhibit nicotinic pharmacology and affect relevant nicotinic receptor sites (e.g., act as a pharmacological agonist to activate nicotinic receptors), and (ii) elicit neurotransmitter secretion, and hence prevent and suppress the symptoms associated with those diseases.
  • nicotinic pharmacology e.g., act as a pharmacological agonist to activate nicotinic receptors
  • neurotransmitter secretion elicit neurotransmitter secretion
  • the active ingredients are expected to have the potential to (i) increase the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts do not cause appreciable adverse side effects (e.g., significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).
  • the pharmaceutical compositions described herein are believed to be safe and effective with regards to treating and preventing a wide variety of conditions and disorders.
  • the scope of the present invention includes all combinations of aspects, embodiments, and preferences herein described. The foregoing and other aspects of the present invention are explained in detail in the detailed description and examples set forth below.
  • Figure 1 illustrates the cumulative penetrated amounts and derived steady state fluxes for tested concentrations of compositions of the present invention during a 24-hour period.
  • the present invention relates to the transdermal administration of (2S)-(4E)- N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, and pharmaceutically acceptable salts thereof.
  • transdermal delivery means a method for drug absorption through the skin, or across the stratum corneum of the epidermis and into the dermis for absorption into the systemic circulation or for local effects.
  • the transdermal route can be effective in delivering (2S)-(4E)-N-methyl-5-(3- (5-isopropoxypyridin)yl)-4-penten-2-amine, which exhibits high affinity and selectivity for, and activity at the ⁇ 4 ⁇ 2 neuronal nicotinic receptor (NNR) subtype.
  • NNR neuronal nicotinic receptor
  • the transdermal route can also be more effective than the oral route in that it can provide for relatively faster or slower (extended) absorption and onset of therapeutic action.
  • the route may be preferred and lead to improved compliance for patients who have difficulty in swallowing tablets, capsules, or other solids (for example, the elderly, the young, and those with impairments, such as dementia), those who have intestinal failure, those whose schedules do not permit dosing throughout the day, and those in extended care facilities.
  • patients who have difficulty in swallowing tablets, capsules, or other solids for example, the elderly, the young, and those with impairments, such as dementia
  • those who have intestinal failure those whose schedules do not permit dosing throughout the day, and those in extended care facilities.
  • active ingredient means (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, as well as any prodrugs thereof and pharmaceutically acceptable salts, hydrates, cocrystals, and solvates of the active ingredient and the prodrugs.
  • ingredients means any excipients, diluents, binders, lubricants, carriers, surfactants, and mixtures thereof that are formulated with the active ingredient.
  • appropriate period of time or “suitable period of time” means the period of time necessary to achieve a desired effect or result.
  • a mixture can be blended until a potency distribution is reached that is within an acceptable range for a given application or use of the blended mixture.
  • Carriers or “vehicles” as used herein refer to carrier materials suitable for transdermal drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non toxic and which does not interact with other components of the composition in a deleterious manner.
  • suitable vehicles for use herein include water, alcohols such as isopropyl alcohol and isobutyl alcohol, polyalcohols such as glycerol, and glycols such as propylene glycol, and esters of such polyols, (e.g., mono-, di-, or tri-glycerides).
  • controlled is meant a metered or measured release of the active ingredient to reduce or minimize peak and valley exposure cycles in blood, plasma, or other biological fluids normally present in some routes of administration of a pharmacologically active agent.
  • an "effective” or an “adequate” permeation enhancer as used herein means a permeation enhancer that will provide the desired increase in skin permeability and correspondingly, the desired depth of penetration, rate of administration, and amount of active ingredient delivered.
  • an effective amount means the amount determined by such considerations as are known in the art for treating or preventing central nervous system disorders, or treating addiction, inflammation or pain in an individual, wherein it must be effective to provide measurable relief in treated individuals such as exhibiting improvements including, but not limited to, more rapid recovery, a more sustained recovery, improvement or elimination of symptoms or reduction of complications, or other measurements as appropriate and known to those skilled in the medical arts.
  • Poration enhancement or “permeation enhancement” as used herein relates to an increase in the permeability of skin to a pharmacologically active agent, namely, so as to increase the rate at which the active ingredient permeates through the skin (i.e., flux) and enters the bloodstream or the local site of action.
  • the enhanced permeation effected by using these enhancers can be observed by measuring the rate of diffusion (or flux) of active ingredient through animal or human skin or a suitable polymeric membrane using a diffusion cell apparatus as described in the examples herein.
  • transdermal delivery applicants intend to include both transdermal and percutaneous administration, i.e., delivery by passage of an active ingredient through the skin and into the bloodstream.
  • sustained is meant extended maintenance of steady state plasma levels of an active ingredient.
  • unit dose means a physically discrete unit that contains a predetermined quantity of active ingredient calculated to produce a desired therapeutic effect.
  • the dosage form can be in any suitable form for transdermal administration, which forms are well known to those of skill in the art.
  • the active blend of a dosage form generally includes one or more pharmaceutically acceptable adhesives, excipients, carriers, diluents, binders, lubricants, glidants, or disintegrants and depends upon the purpose for which the active ingredient is being applied.
  • transdermal compositions include other ingredients including, but not limited to, excipients, diluents, carriers, permeation enhancers, and mixtures thereof.
  • the active ingredients that are the subject of the present invention are (2S)- (4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, and pharmaceutically acceptable salts thereof.
  • the formula for the free base is shown below:
  • the ideal pH for transdermal drug delivery is typically in the range of from about 3.5 to about 9.5. Since the instant active ingredient is itself basic (i.e., it includes two basic nitrogen atoms), it tends to produce solutions in the upper end of this pH range when the free base form is placed in water. For this reason, it may be desirable to neutralize at least one of the nitrogens, using a pharmaceutically acceptable acid to form one or more pharmaceutically acceptable salt of the free base .
  • Suitable pharmaceutically acceptable salts include inorganic acid addition salts such as chloride, bromide, sulfate, phosphate, and nitrate; organic acid addition salts such as acetate, galactarate, propionate, succinate, lactate, glycolate, malate, tartrate, citrate, maleate, fumarate, methanesulfonate, p-toluenesulfonate, benzoate, hydroxybenzoate, edisylate, orotate, R-mandelate and ascorbate; salts with amino acids such as lysine monohydrochloride, aspartate and glutamate.
  • the salts may be in some cases hydrates or ethanol solvates.
  • the acids also help with the permeability of the active agent through the skin. That is, when the neutralizing agent is a fatty acid, it can neutralize one or both of the basic nitrogen atoms on the active ingredient, while at the same time increasing the permeability of the active ingredient through the skin.
  • the active ingredient is present as a fatty acid salt, wherein one or both of the basic nitrogens is reacted with the acid group in the fatty acids to form a salt.
  • the salts can be present in a 1 :1 or 1 :2 molar ratio of active ingredient to fatty acid.
  • the reaction of a fatty acid and an amine to form a fatty acid carboxylate salt is well known to those of skill in the art.
  • the fatty acids typically have between 4 and 20 carbon atoms, and, more typically between 10 and 18 carbon atoms. Stearic acid is one representative fatty acid.
  • the synthesis of (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2- amine can be carried out, for example, using procedures described in U.S. Patent No. 6,958,399, as noted above herein incorporated by reference.
  • the synthesis of salts of (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine can be accomplished by combining (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4- penten-2-amine with various inorganic and organic acids in appropriate solvents, as exemplified in U.S.
  • compositions for transdermal administration include (2S)-(4E)-N-methyl- 5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, or its pharmaceutically acceptable salts, including fatty acid salts, and optionally can also include other ingredients including, but not limited to, carriers and excipients, such as permeation enhancers which promote transdermal absorption of the active ingredient after transdermal administration.
  • carriers and excipients such as permeation enhancers which promote transdermal absorption of the active ingredient after transdermal administration.
  • permeation enhancers which promote transdermal absorption of the active ingredient after transdermal administration.
  • the amount of active ingredient absorbed depends on many factors.
  • these factors include the active ingredient concentration, the active ingredient delivery vehicle, the skin contact time, the area of the skin dosed, the ratio of the ionized and unionized forms of the active ingredient at the pH of the absorption site, the molecular size of the active ingredient molecule, and the active ingredient's relative lipid solubility.
  • the transdermal device for delivering the active ingredients described herein can be of any type known in the art, including the monolithic, matrix, membrane, and other types typically useful for administering active ingredients by the transdermal route.
  • Such devices are disclosed in U.S. Pat. Nos. 3,996,934; 3,797,494; 3,742,951 ; 3,598,122; 3,598,123; 3,731 ,683; 3,734,097; 4,336,243; 4,379,454; 4,460,372; 4,486,193; 4,666,441 ; 4,615,699; 4,681 ,584; and 4,558,580 among others; the disclosures of which are incorporated herein by reference.
  • the active ingredient, or pharmaceutically acceptable salt thereof is typically present in a solution or dispersion, which can be in the form of a gel, a solution, or a semi-solid, and which aids in active ingredient delivery through the stratum corneum of the epidermis and to the dermis for absorption.
  • Membrane devices typically have four layers: (1 ) an impermeable backing, (2) a reservoir layer, (3) a membrane layer (which can be a dense polymer membrane or a microporous membrane), and (4) a contact adhesive layer which either covers the entire device surface in a continuous or discontinuous coating or surrounds the membrane layer.
  • Examples of materials that may be used to act as an impermeable layer are high, medium, and low density polyethylene, polypropylene, polyvinylchloride, polyvinylidene chloride, polycarbonate, polyethylene terepthalate, and polymers laminated or coated with aluminum foil. Others are disclosed in the standard transdermal device patents mentioned herein.
  • the outer edge of the backing layer can overlay the edge of the reservoir layer and be sealed by adhesion or fusion to the diffusion membrane layer. In such instances, the reservoir layer need not have exposed surfaces.
  • the reservoir layer is underneath the impermeable backing and contains a carrier liquid, typically water and/or an alcohol, or polyol or ester thereof, and may or may not contain the active ingredients.
  • the reservoir layer can include diluents, stabilizers, vehicles, gelling agents, and the like in addition to the carrier liquid and active ingredients.
  • the diffusion membrane layer of the laminate device can be made of a dense or microporous polymer film that has the requisite permeability to the active ingredient and the carrier liquid.
  • the membrane is impermeable to ingredients other than the active ingredient and the carrier liquid, although when buffering at the skin surface is desired, the membrane should be permeable to the buffer in the composition as well.
  • Examples of polymer film that may be used to make the membrane layer are disclosed in U.S. Pat. Nos. 3,797,454 and 4,031 ,894, each herein incorporated by reference.
  • the preferred materials are polyurethane, ethylene vinyl alcohol polymers, and ethylene/vinyl acetate.
  • a reservoir layer comprising the active ingredient in a buffer solution optional further comprising a penetration enhancer.
  • a membrane layer (which can be a dense polymer membrane or a microporous membrane), and
  • a contact adhesive layer which either covers the entire device surface in a continuous or discontinuous coating or surrounds the membrane layer.
  • composition above comprised in the reservoir the active ingredient in phosphate buffered saline solution.
  • hydroxybenzoate salt of the active ingredient is used in the composition above.
  • the active ingredient in the reservoir of the composition above is present in a concentration of from 30 to 200 mg per gram of saline solution. In yet a further embodiment the concentration of the active ingredient in the reservoir of the composition above is 35 or 135 mg per gram of saline solution.
  • the second class of transdermal systems is represented by monolithic matrices.
  • monolithic devices are U.S. Pat. No. 4,291 ,014, U.S. Pat. No. 4,297,995, U.S. Pat. No. 4,390,520, and U.S. Pat. No. 4,340,043, each herein incorporated by reference. Others are known to those of ordinary skill in this art.
  • Monolithic and matrix type barrier transdermal devices typically include:
  • Porous polymers or open-cell foam polymers such as polyvinyl chloride (PVC), polyurethanes, polypropylenes, and the like;
  • Gels of liquids typically including water and/or hydroxyl-containing solvents such as ethanol, and often containing gelling agents such PVP, carboxymethylcellulose (CMC), hydroxypropylcellulose such as sold under the tradename Klucel®, HPMC, alginates, kaolinate, bentonite, or montmorillonite, other clay fillers, stearates, silicon dioxide particles, and the like;
  • gelling agents such PVP, carboxymethylcellulose (CMC), hydroxypropylcellulose such as sold under the tradename Klucel®, HPMC, alginates, kaolinate, bentonite, or montmorillonite, other clay fillers, stearates, silicon dioxide particles, and the like;
  • Nonwoven materials made of textiles, celluloses, polyurethanes, polyester, or other fiber;
  • Sponges which can be formed from natural or foamed polymers
  • Adhesives ideally dermatologically-acceptable pressure sensitive adhesives, for example, silicone adhesives or acrylic adhesives.
  • Polymeric Barrier Materials include, but are not limited to:
  • Polycarbonates such as those formed by phosgenation of a dihydroxy aromatic such as bisphenol A, including materials are sold under the trade designation Lexan® (the General Electric Company);
  • Polyvinylchlorides such as Geon® 121 (B. G. Goodrich Chemical Company);
  • nylons such as polyhexamethylene adipamide, including NOMEX® (E. I. DuPont de Nemours & Co.).
  • Modacrylic copolymers such as DYNEL®, are formed of polyvinylchloride (60 percent) and acrylonitrile (40 percent), styrene-acrylic acid copolymers, and the like.
  • Polysulfones for example, those containing diphenylene sulfone groups, for example, P-1700 (Union Carbide Corporation).
  • Halogenated polymers for example, polyvinylidene fluoride, such as Kynar® (Pennsalt Chemical Corporation), polyvinylfluoride, such as Tedlar® (E. I. DuPont de Nemours & Co.), and polyfluorohalocarbons, such as Aclar® (Allied Chemical Corporation).
  • Polychlorethers for example, Penton® (Hercules Incorporated), and other thermoplastic polyethers.
  • Acetal polymers for example, polyformaldehydes, such as Delrin® (E. I. DuPont de Nemours & Co.).
  • Acrylic resins for example, polyacrylonitrile, polymethyl methacrylate (PMMA), poly n-butyl methacrylate, and the like.
  • polymers such as polyurethanes, polyimides, polybenzimidazoles, polyvinyl acetate, aromatic and aliphatic, polyethers, cellulose esters, e.g., cellulose triacetate; cellulose; colledion (cellulose nitrate with 11% nitrogen); epoxy resins; olefins, e.g., polyethylene, polypropylene; polyvinylidene chloride; porous rubber; cross linked poly(ethylene oxide); cross-linked polyvinylpyrrolidone; cross-linked polyvinyl alcohol); polyelectrolyte structures formed of two ionically associated polymers of the type as set forth in U.S. Pat. Nos.
  • the thickness of the membrane or barrier can be reduced. However, the thickness should not be reduced to the point where it is likely to tear, or to a point where the amount of active ingredient which can be administered is too low.
  • the transdermal drug delivery compositions typically include a contact adhesive layer to adhere the device to the skin.
  • the active agent may, in some embodiments, reside in the adhesive.
  • Exemplary adhesives include polyurethanes; acrylic or methacrylic resins such as polymers of esters of acrylic or methacrylic acid with alcohols such as n- butanol, n-pentanol, isopentanol, 2-methylbutanol, 1 -methylbutanol, 1- methylpentanol, 2-methylpentanol, 3-methylpentanol, 2-ethylbutanol, isooctanol, n- decanol, or n-dodecanol, alone or copolymerized with ethylenically unsaturated monomers such as acrylic acid, methacrylic acid, acrylamide, methacrylamide, N- alkoxymethyl acrylamides, N-alkoxymethyl methacrylamides, N-tertbutylacrylamide, itaconic acid, vinylacetate, N-branched alkyl maleamic acids wherein the alkyl group has 10 to 24 carbon atoms, glycol
  • silicone adhesives include silicone elastomers based on monomers of silanes, halosilanes, or CMS alkoxysilanes, especially polydimethylsiloxanes which may be used alone or formulated with a silicone tackifier or silicone plasticizer which are selected from medically acceptable silicone fluids, i.e. non-elastomeric silicones based on silanes, halosilanes or C 1-18 alkoxysilanes.
  • Typical silicone adhesives are available from Dow Corning under the tradename SILASTIC®.
  • Transdermal compositions can include a variety of components, including a liquid vehicle, typically a C 2-4 alkanol such as ethanol, isopropanol, n-propanol, butanol, a polyalcohol or glycol such as propylene glycol, butylene glycol, hexylene glycol, ethylene glycol, and/or purified water.
  • a liquid vehicle typically a C 2-4 alkanol such as ethanol, isopropanol, n-propanol, butanol, a polyalcohol or glycol such as propylene glycol, butylene glycol, hexylene glycol, ethylene glycol, and/or purified water.
  • the vehicle is typically present in an amount of between about 5 and about 75% w/w, more typically, between about 15.0% and about 65.0% w/w, and, preferably, between about 20.0 and 55.0% w/w.
  • Water augments the solubility of hydrophilic active agents in the composition, and accelerates the release of lipophilic active agents from a composition.
  • Alcohols such as ethanol, increase the stratum corneum liquid fluidity or function to extract lipids from the stratum corneum.
  • the glycols can also act as permeation enhancers.
  • transdermal delivery depends among others on sufficient flux of the active ingredient across skin, and sufficient surface area of skin, to produce an efficacious plasma concentration of the active ingredient.
  • the practical surface area of a transdermal system is limited from approximately 4 to 100 cm 2 .
  • the therapeutic transdermal administration of many active ingredients requires an increase in the inherent skin permeability to obtain the necessary flux. Accordingly, active ingredients have been developed which enhance percutaneous absorption of the active ingredients to be administered.
  • Permeation enhancers are described, for example, in U.S. Patent Nos. 5,785,991 ; 4,764,381 ; 4,956,171 ; 4,863,970; 5,453,279; 4,883,660; 5,719,197, and in the literature "Pharmaceutical Skin Penetration Enhancement", J. Hadgraft, Marcel Dekker, Inc. 1993; "Percutaneous Absorption", R. Bronaugh, H. Maibach, Marcel Dekker, Inc. (1989), B. W. Barry, "Penetration Enhancers in Skin Permeation", Proceedings of the 13th international Symposium on Controlled Release of Bioactive Materials, ed. by Chaudry & Thies, Controlled Release Society, Lincolnshire, III., pp.
  • the permeation enhancers should both enhance the permeability of the stratum corneum, and be non-toxic, non-irritant and non-sensitizing on repeated exposure.
  • Representative permeation enhancers include, for example, sucrose monococoate, glycerol monooleate, sucrose monolaurate, glycerol monolaureate, diethylene glycol monoalkyl ethers such as diethylene glycol monoethyl or monomethyl ether (Transcutol® P), ester components such as propylene glycol monolaurate, methyl laurate, and lauryl acetate, monoglycerides such as glycerol monolaurate, fatty alcohols such as lauryl alcohol, and 2-ethyl-1 ,3 hexanediol alone or in combination with oleic acid.
  • the transdermal compositions are provided with skin permeation enhancing benefits by combining the active ingredients with saturated fatty alcohols, or forming salts of the active ingredients with one or more fatty acids, such as those of the formula CH 3 -(CH 2 ) P -CH 2 OH or CH 3 -(CH 2 ) n -CH 2 COOH respectively, in which n is an integer from 8 to 22, preferably 8 to 12, most preferably 10, or an unsaturated fatty alcohol or fatty acid given by the formula CH3-(C n H 2 ( n - ⁇ ) )- OH or CH 3 -(C n H 2( n-x ) )-COOH respectively in which n is an integer from 8 to 22 and x is the number of double bonds; and preferably also a second component that is a monoalkyl ether of diethylene glycol, preferably diethylene glycol monoethyl ether or diethylene glycol monomethyl ether, in a vehicle or carrier composition, integrated by an C-
  • a binary system including a combination of oleic acid or oleic alcohol and a lower alcohol, or a combination of a lower alkyl ester of a polycarboxylic acid, an aliphatic monohydroxy alcohol and an aliphatic diol, can be used.
  • Representative permeation enhancers include fatty alcohols and fatty acids, and monoalkyl ethers of diethylene glycol such as diethylene glycol monoethyl ether or diethylene glycol monomethyl ether.
  • the fatty alcohols are typically present in an amount of between about 0.1 and about 20.0% w/w, preferably between about 0.2 and about 10.0% w/w, and more preferably, between about 0.4 and about 3.0% w/w.
  • the diethylene glycol monoalkyl ethers are typically present in an amount up to 40.0% w/w, preferably between about 0.2 and 25.0% w/w, and, more preferably, between about 2.0 and about 8.0% w/w.
  • the fatty alcohol is mainly distributed to the stratum corneum because of its lipophilicity and interacts with the stratum corneum lipids.
  • the diethylene glycol monoalkyl ethers dissolve both hydrophilic and a lipophilic active agents therein, and facilitates the penetration of the active agents to the skin.
  • Glycols such as propylene glycol, act as a cosolvent of the active agents, and thus increase their solubility in the composition. Further, they tend to solvate the intracellular keratin of the stratum corneum, and thus enhance drug mobility and skin hydration.
  • Gelling agents such as carbomer, carboxyethylene or polyacrylic acid such as Carbopol® 980 or 940 NF, 981 or 941 NF, 1382 or 1342 NF, 5984 or 934 NF, ETD 2020, 2050, 934P NF, 971 P NF, 974P NF, Noveon® AA-1 USP, etc; cellulose derivatives such as ethylcellulose, hydroxypropylmethylcellulose (HPMC), ethylhydroxyethylcellulose (EHEC), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC) (Klucel®, different grades), hydroxyethylcellulose (HEC) (Natrosol® grades), HPMCP 55, Methocel® grades, etc; natural gums such as arabic, xanthan, guar gums, alginates, etc; polyvinylpyrrolidone derivatives such as Kollidon® grades; polyoxyethylene polyoxypropylene copolymers such as
  • Representative gelling agents include, but are not limited to, Carbopol® 980 NF, Lutrol® F 127, Lutrol® F 68 and Noveon® AA-1 USP.
  • the gelling agent is present from about 0.2 to about 30.0% w/w, depending on the type of polymer. Preservatives
  • the transdermal compositions can also include one or more preservatives and/or antioxidants.
  • Representative preservatives include quaternary ammonium salts such as lauralkonium chloride, benzalkonium chloride, benzododecinium chloride, cetyl pyridium chloride, cetrimide, domiphen bromide; alcohols such as benzyl alcohol, chlorobutanol, o-cresol, phenylethyl alcohol; organic acids or salts thereof such as benzoic acid, sodium benzoate, potassium sorbate, parabens; or complex forming agents such as ethylenediaminetetraacetic acid (EDTA).
  • Representative antioxidants include butylhydroxytoluene, butylhydroxyanisole, ethylenediaminetetraacetic acid and its sodium salts, D,L-alpha tocoferol.
  • diluents such as cellulose, microcrystalline cellulose, hydroxypropyl cellulose, starch, hydroxypropylmethyl cellulose and the like. Excipients can be added to adjust the tonicity of the composition, such as sodium chloride, glucose, dextrose, mannitol, sorbitol, lactose and the like. Acidic or basic buffers can also be added to control the pH. Co-solvents or solubilizers such as glycerol, polyethylene glycols, polyethylene glycols derivatives, polyethylene glycol 660 hydroxystearate (Solutol HS15 from BASF), butylene glycol, hexylene glycol, and the like, can also be added.
  • the administration of the active agent can be controlled by using controlled release compositions, which can provide rapid or sustained release, or both, depending on the compositions.
  • particulate drug delivery vehicles known to those of skill in the art which can include the active ingredients, and deliver them in a controlled manner.
  • examples include particulate polymeric drug delivery vehicles, for example, biodegradable polymers, and particles formed of non-polymeric components. These particulate drug delivery vehicles can be in the form of powders, microparticles, nanoparticles, microcapsules, liposomes, and the like.
  • the active agent is in particulate form without added components, its release rate depends on the release of the active agent itself.
  • the active agent is in particulate form as a blend of the active agent and a polymer, the release of the active agent is controlled, at least in part, by the removal of the polymer, typically by dissolution or biodegradation.
  • the compositions can provide an initial rapid release of the active ingredient followed by a sustained release of the active ingredient.
  • U.S. Patent No. 5,629,011 provides examples of this type of composition and is incorporated herein by reference in its entirety.
  • transdermal compositions that use transdermal delivery to deliver nicotine in a time-release manner (such as rate-controlling membranes), including currently marketed nicotine replacement therapies. These are also suitable for administering the metanicotines described herein.
  • the transdermal dosage form is not a "patch," but rather, a semisolid dosage form such as a gel, cream, ointment, liquid, etc.
  • a semisolid dosage form such as a gel, cream, ointment, liquid, etc.
  • the dosage form can include other active and inactive components typically seen in semisolid dosage forms used to treat pain.
  • active and inactive components typically seen in semisolid dosage forms used to treat pain.
  • these include, but are not limited to, menthol, wintergreen, capsaicin, aspirin, NSAIDs, narcotic agents (e.g. fentanyl), alcohols, oils such as emu oil, and solvents such as DMSO.
  • the active ingredients can also be delivered via iontophoresis.
  • Iontophoresis is a non-invasive method of propelling high concentrations of a charged substance, such as the active ingredients described herein, transdermal ⁇ by repulsive electromotive force.
  • the technique involves using a small electrical charge applied to an iontophoretic chamber containing a similarly charged active agent and its vehicle. The skin's permeability is altered upon application of the charge, and this increases migration of the active ingredient into the epidermis.
  • one or two chambers are filled with a solution containing one or more of the active agents and a solvent (the "vehicle").
  • the positively charged chamber (“the anode”) will repel a positively charged chemical into the skin.
  • the negatively charged chamber (“the cathode”), will repel a negatively charged chemical into the skin. Because the active ingredients are cationic, they are administered iontophoretically via the anode.
  • Iontophoresis can be used to transdermal ⁇ deliver the active agents, using active transportation within an electric field, typically by electromigration and electroosmosis. These movements are typically measured in units of chemical flux, commonly ⁇ mol/cm 2 *h.
  • the isoelectric point of the skin is approximately 4. Under physiological conditions, where the surface of the skin is buffered at or near 7.4, the membrane has a net negative charge, and electroosmotic flow is from anode (-) to cathode (+). Electroosmosis augments the anodic delivery of the (positively charged) active agents described herein.
  • iontophoretic transport There are a number of factors that influence iontophoretic transport, including skin pH, the concentration and characteristics of the active agent, ionic competition, molecular size, current, voltage, time applied and skin resistance.
  • the current density of the treatment electrode is perhaps the most important variable, relative to the degree of ion transfer. Comparable iontophoretic doses delivered at low currents over longer periods are more effective than those delivered by high currents over short periods.
  • Iontophoresis devices include two electrodes, which are typically attached to a patient, each connected via a wire to a microprocessor controlled electrical instrument.
  • the active agents are placed under one or both of the electrodes, and are delivered into the body as the instrument is activated.
  • the instrument is typically designed to regulate both current flow and application time. Examples of such instruments are described in U.S. Patent Nos. 5,254,081 , and 5,431 ,625, the contents of which are hereby incorporated by reference. Power for these devices is usually provided by DC batteries, which when providing power for the microprocessor controlled circuitry allow application of a voltage to the electrodes to create a regulated current flow. Wearable iontophoretic systems have been developed in which the electrical circuitry and power supplied are integrated into a single patch. These systems are advantageous in that they do not have external wires, and they are much smaller in size. Examples of such systems can be found in U.S. Patent Nos. 5,358,483; 5,458,569; 5,466,217; 5,605,536; and 5,651 ,768, the contents of which are hereby incorporated by reference.
  • ions are delivered into the body from an aqueous drug reservoir contained in the iontophoretic device, and counter ions of opposite charge are delivered from a "counter reservoir.”
  • Solutions containing the active ingredient, and also solutions of the counter ions, can be stored remotely and introduced to an absorbent layer of the iontophoresis electrode at the time of use. Examples of such systems are described in U.S. Pat. Nos. 5,087,241 ; 5,087,242; 5,846,217; and 6,421 ,561 , the contents of which are hereby incorporated by reference.
  • the active agents can be pre-packaged in dry form into the electrode(s). This approach requires a moisture activation step at the time of use.
  • Solutions of the active agents can be co-packaged with the iontophoretic device, ideally positioned apart from the electrodes and other metallic components until the time of use.
  • This technique, and suitable devices are described, for example, in U.S. Patent Nos. 5,158,537; 5,288,289; 5,310,404; 5,320,598; 5,385,543; 5,645,527; 5,730,716; and 6,223,075, each of which is incorporated by reference.
  • a co-packaged electrolyte constituent liquid is stored remotely from the electrodes, in a rupturable container and a mechanical action step at the time of use induces a fluid transfer to a receiving reservoir adjacent to the electrodes.
  • the active agents can be present in a pre-formed gel, as described in U.S. Patent No. 4,383,529, incorporated by reference.
  • a preformed gel containing the active agent can be transferred into an electrode receptacle at the time of use.
  • This system can be advantageous in that it provides a precise pre-determined volume of the gel, thus preventing over-filling. Further, since the active agent is present in a gel composition, it is less likely to leak during storage or transfer.
  • the transdermal compositions can be used to treat or prevent a condition or disorder in a subject susceptible to such a condition or disorder. Treatment includes amelioration of the symptoms of a disorder.
  • prevention or “prophylaxis” include inhibition of the progression of a disorder, including but not limited to providing protective effects, inhibiting or delaying the onset of a disorder, or amelioration of the reoccurrence of a disorder.
  • the method involves administering an effective amount of (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2- amine, or one of its pharmaceutically acceptable salts, including fatty acid salts, such as stearic acid salts.
  • the instant active ingredients are modulators of the ⁇ 4 ⁇ 2 NNR subtype, characteristic of the CNS, and can be used for preventing and/or treating various conditions or disorders, including those of the CNS, in subjects which have or are susceptible to such conditions or disorders, by modulation of ⁇ 4 ⁇ 2 NNRs.
  • the active ingredients have the ability to selectively bind to the ⁇ 4 ⁇ 2 NNRs and express nicotinic pharmacology (e.g., to act as partial agonists, agonists, antagonists and/or inverse agonists).
  • the active ingredients described herein when administered in effective amounts to patients in need thereof, provide some degree of prevention of the progression of the CNS disorder (i.e., providing protective effects), amelioration of the symptoms of the CNS disorder, and/or amelioration of the reoccurrence of the CNS disorder.
  • the active ingredient can be used to treat and/or prevent those types of conditions and disorders for which other types of nicotinic compounds have been proposed as therapeutics. See, for example, the references previously listed in the "Background of the Invention" section, as well as Williams et al., Drug News Perspec. 7(4): 205 (1994), Arneric et al., CNS Drug Rev. 1 (1 ): 1-26 (1995), Arneric et al., Exp. Opin. Invest. Drugs 5(1 ): 79-100 (1996), Bencherif et al., J. Pharmacol. Exp. Ther. 279: 1413 (1996), Lippiello et al., J. Pharmacol. Exp. Ther.
  • the active ingredients and their pharmaceutical compositions are useful in the treatment and/or prevention of a variety of CNS disorders, including neurodegenerative disorders, neuropsychiatric disorders, neurologic disorders, and addictions.
  • diseases and conditions that the active ingredients and pharmaceutical compositions described herein can be used to treat and/or prevent are: age-associated memory impairment, mild cognitive impairment, presenile dementia, early onset Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, Lewy body dementia, HIV-dementia, vascular dementia, Alzheimer's disease, stroke, AIDS dementia complex, attention deficit disorder, attention deficit hyperactivity disorder, dyslexia, schizophrenia, schizophreniform disorder, schizoaffective disorder, Parkinsonism including Parkinson's disease, Pick's disease, Huntington's chorea, tardive dyskinesia, hyperkinesia, progressive supranuclear palsy, Creutzfeld-Jakob disease, multiple sclerosis, amyotrophic lateral sclerosis, epilepsy, mania, anxiety
  • One aspect of the present invention further provides use of the transdermal composition of the present invention comprising the active ingredient in the manufacturing of a medicament for treating or preventing disorders selected from the group consisting of Alzheimer's Disease, mild to moderate dementia of the Alzheimer's type, attention deficit disorder, attention deficit hyperactivity disorder, mild cognitive impairment, age-associated memory impairment, schizophrenia, and cognitive dysfunction in schizophrenia.
  • Another aspect of the present invention includes the use of a transdermal composition of the present invention for treating or preventing disorders selected from the group consisting of Alzheimer's Disease, mild to moderate dementia of the Alzheimer's type, attention deficit disorder, attention deficit hyperactivity disorder, mild cognitive impairment, age-associated memory impairment, schizophrenia, and cognitive dysfunction in schizophrenia.
  • Another aspect of the present invention includes a method for the treatment or prevention of disorders selected from the group consisting of Alzheimer's Disease, mild to moderate dementia of the Alzheimer's type, attention deficit disorder, attention deficit hyperactivity disorder, mild cognitive impairment, age-associated memory impairment, schizophrenia, and cognitive dysfunction in schizophrenia comprising administering a composition of the present invention.
  • the active ingredients and their pharmaceutical compositions can be used to treat and/or prevent attentional disorders; to provide neuroprotection; to treat convulsions and multiple cerebral infarcts; to treat cognitive disorders, mood disorders, compulsions and addictive behaviors; to provide analgesia; to control inflammation (such as mediated by cytokines and nuclear factor kappa B) and treat inflammatory disorders; to provide pain relief (e.g., relief from acute pain, chronic pain, neurologic pain, neuropathic pain, female specific pain, post-surgical pain, or cancer pain); and to treat infections (as anti-infectious agents for treating bacterial, fungal and viral infections).
  • attentional disorders to provide neuroprotection; to treat convulsions and multiple cerebral infarcts; to treat cognitive disorders, mood disorders, compulsions and addictive behaviors; to provide analgesia; to control inflammation (such as mediated by cytokines and nuclear factor kappa B) and treat inflammatory disorders; to provide pain relief (e.g., relief from acute pain,
  • the treatment or prevention of diseases, disorders and conditions occurs without appreciable adverse side effects (e.g., significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).
  • the active ingredients and compositions described herein, when employed in effective amounts, can modulate the activity of the ⁇ 4 ⁇ 2 NNRs without appreciable interaction with the NNR subtypes that characterize the human ganglia (as demonstrated by their lack of ability to elicit nicotinic function in adrenal chromaffin tissue) or skeletal muscle (as demonstrated by their lack of ability to elicit nicotinic function in cell preparations expressing muscle-type NNRs).
  • these active ingredients are capable of treating and/or preventing diseases, disorders and conditions without eliciting significant side effects associated with activity at ganglionic and neuromuscular sites.
  • administration of the active ingredients provides a therapeutic window in which treatment of certain diseases, disorders and conditions is provided, and certain side effects are avoided. That is, an effective dose of the active ingredient is sufficient to provide the desired effects upon the disease, disorder or condition, but is insufficient (i.e., is not at a high enough level) to provide undesirable side effects.
  • transdermal compositions described herein can also be used to replace traditional transdermal nicotine patch devices, or "patches", used in connection with smoking cessation. Due to substantial interpatient variability of nicotine blood levels, it is unlikely that a single dose of nicotine replacement therapy can be optimal for all humans, and, accordingly, they can be provided in various dosage levels to accommodate different patients.
  • compositions described herein will provide an acceptable risk/benefit in terms of adequate safety and provision of smoking cessation therapy.
  • patient-controlled, flexible treatment described herein will eliminate entirely, or at least substantially reduce, use of tobacco in humans who undergo such treatment.
  • Forms of such tobacco use are well known and include cigarettes, cigars and pipes, as well as "smokeless" tobacco products such as tobacco to be chewed or otherwise placed and kept in the mouth of humans.
  • the active ingredients are typically present in an amount, per patch, of between about 1 and 200 milligrams. Patches are configured in various sizes to give a range of skin contact surface areas to modulate the dose absorbed.
  • the appropriate dosage for each patient will be governed by the human's personal tolerance to nicotine, and the ability of the active ingredient to effectively cross the stratum corneum of the epidermis and be absorbed in sufficient quantity to elicit the desired therapeutic response.
  • a broad range of daily dose exposure is likely to be observed in the treated population.
  • the patients may increase or decrease the amount of use, as required.
  • the concentration of the active ingredients is decreased over time, as the patient lowers his/her perceived need to smoke.
  • Long-term treatment may be appropriate for certain individuals who require longer periods of treatment. For example, it may require as long as, for example, up to one year after commencement of treatment, or as little as six to ten weeks (or less).
  • the therapy can be patient-controlled, it may be the patient who determines what levels of the active agents are required over the course of treatment, or at various stages of treatment, in order to abate, avoid, or minimize his/her need to smoke. For example, should the patient have a strong urge to use tobacco products, this might indicate to the patient that a higher dosage level is required.
  • Patients may refer to and/or rely on a behavioral support program which may include, for example, printed instructions and/or labels, or other oral instructions, advice or information given by qualified individuals who have been trained in giving advice on methods of treatment using the compositions described herein. Additionally, the patient may consult with a health care provider. However, the patients themselves, once having the educational benefit and guidance of the behavioral support program and/or the health care provider, will ideally be able to assess their own progress and respond appropriately in adjusting their dosage levels.
  • this form of therapy will avoid the symptoms associated with other nicotine therapy, including, without limitation, irritability, restlessness, insomnia, drowsiness, difficulty concentrating (e.g. impaired task performance), anxiety, hunger, cravings, vomiting, diarrhea, cold sweat, blurred vision, difficulty hearing, mental confusion, weakness, and/or fainting.
  • compositions can also be used to treat other addictions, such as alcohol, narcotics (including opiates such as oxycodone, morphine, heroine, and the like), prescription drugs, gambling, and the like.
  • addictions such as alcohol, narcotics (including opiates such as oxycodone, morphine, heroine, and the like), prescription drugs, gambling, and the like.
  • abdominal guinea pig skin can be performed to evaluate the ability of a transdermal composition to deliver an active ingredient in pharmaceutically useful levels to a patient in need of treatment. These can be performed using a diffusion chamber, such as a Franz Vertical Diffusion Cell.
  • the skin can be obtained from female Guinea pigs, 8 to 16 months of age, ideally shaved and free of lesions.
  • a section of full thickness abdominal skin can be surgically excised and mounted between the sections of a vertical diffusion cell with the epidermal layer facing up.
  • a transdermal device can be applied over the epidermal layer while the dermal layer is in contact with a receptor solution of PBS (or other suitable isotonic solution), with or without a suitable quantity of polyoxyethylene 20 oleyl ether (Oleth 20) or other surfactant to prevent foaming, at pH 7.4).
  • the receptor chamber can be maintained at a suitable temperature, for example, around 35 0 C, and the permeation studies conducted under occlusive or non-occlusive conditions.
  • samples can be withdrawn from the receptor solution and the receptor chamber refilled with fresh solution. The samples can be analyzed, for example, using a high performance liquid chromatography (HPLC) method.
  • HPLC high performance liquid chromatography
  • Transdermal flux (mcg/cm 2 /h) can be determined from the steady-state slope of the plot of the cumulative amount of the active ingredient(s) permeating through the skin versus time. After steady-state is established, the linear portion of the plot can be used to calculate the flux from the slope.
  • Bronaugh diffusion cells were used for in vitro penetration studies, which were carried out to determine the flux (i.e. the speed by which the compound penetrates skin) and total cumulated amount penetrated of 14 C-active ingredient.
  • the compound was dissolved in water at two concentrations, 35 and 135 mg/g. Pig-ear full- thickness skin (dermatomed to approx. 900 ⁇ m thick) was used as the membrane.
  • the receiver compartment contained phosphate buffered saline (pH 7.4) and the temperature was maintained at 32°C. The compound solutions were applied onto the stratum corneum. Receiver compartment samples (2, 4, 8 12 and 14 h) were assayed by liquid scintillation counting.
  • the transdermal flux ( ⁇ g/cm 2 /h) can be determined from the steady-state slope of the plot of the cumulative amount of active ingredient permeating through the skin versus time. After steady-state was established, the linear portion of the plot was used to calculate the flux from the slope.
  • the active ingredient has advantageous properties for transdermal use as the steady state flux falls in the same range as for other active ingredients classified as successful transdermals, i.e. 0.2-40 ⁇ g/cm 2 /h (i.e. clonidine, estradiol, fentanyl, nicotine, scopolamine, testosterone). Higher flux can be expected at higher concentrations of active ingredient, e.g. 200 mg/g which is the maximal solubility in water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)

Abstract

D'une manière générale, la présente invention concerne l'administration transdermique de 2S)-(4E)-N-méthyl-5-(3-(5-isopropoxypyridin)yl)-4-pentén-2-amine ou de sels pharmaceutiquement acceptables de celle-ci. L'administration transdermique peut être effectuée en utilisant des dispositifs d'administration transdermique de médicament, des formes galéniques semi-solides ou une iontophorèse. Les dispositifs d'administration de médicament et/ou les formes galéniques semi-solides peuvent fournir une libération instantanée ou une libération soutenue ou des combinaisons de celles-ci, et peuvent comporter des amplificateurs de perméation et d'autres composants pour aider le transfert des médicaments à travers le derme, spécialement l'épiderme. Les compositions peuvent être utilisées pour traiter et/ou prévenir toute indication que les ingrédients actifs peuvent traiter et prévenir, mais pour délivrer de la 2S)-(4E)-N-méthyl-5-(3-(5-isopropoxypyridin)yl)-4-pentén-2-amine ou des sels pharmaceutiquement acceptables de celle-ci, de manière efficace, dont les troubles du système nerveux central, les dépendances, la douleur et l'\inflammation.
PCT/US2008/071638 2007-07-31 2008-07-30 Administration transdermique de (2s)-(4e)-n-méthyl-5-(3-(5-isopropoxypyridin)yl)-4-pentén-2-amine WO2009018373A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2695214A CA2695214A1 (fr) 2007-07-31 2008-07-30 Administration transdermique de (2s)-(4e)-n-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine
BRPI0815070A BRPI0815070A2 (pt) 2007-07-31 2008-07-30 Administração transdérmica de (2s)-(4e)-n-metil-5-(3- (5-isopropoxipiridin) il-4-penten-2-amina
US12/671,232 US20100247617A1 (en) 2007-07-31 2008-07-30 Transdermal Administration Of (2S)-(4E)-N-Methyl-5-(3-(5-Isopropoxypyridin)yl)-4-Penten-2-Amine
JP2010520158A JP2010535237A (ja) 2007-07-31 2008-07-30 （２ｓ）−（４ｅ）−ｎ−メチル−５−（３−（５−イソプロポキシピリジン）イル）−４−ペンテン−２−アミンの経皮投与
EP08796889A EP2182932A2 (fr) 2007-07-31 2008-07-30 Administration transdermique de (2s)-(4e)-n-méthyl-5-(3-(5-isopropoxypyridin)yl)-4-pentén-2-amine
CN200880101391A CN101772343A (zh) 2007-07-31 2008-07-30 (2s)-(4e)-n-甲基-5-(3-(5-异丙氧基吡啶)基)-4-戊烯-2-胺的经皮给药
NZ582826A NZ582826A (en) 2007-07-31 2008-07-30 Transdermal composition comprising (2S)-(4E)-N-methyl-5-(5-isopropoxy-pyridin-3-yl)-4-penten-2-amine
AU2008282205A AU2008282205A1 (en) 2007-07-31 2008-07-30 Transdermal administration of (2S)-(4E)-N-methyl-5-(3-( 5-isopropoxypyridin)yl)-4-penten-2-amine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95306207P 2007-07-31 2007-07-31
US60/953,062 2007-07-31

Publications (2)

Publication Number Publication Date
WO2009018373A2 true WO2009018373A2 (fr) 2009-02-05
WO2009018373A3 WO2009018373A3 (fr) 2009-03-26

Family

ID=40297684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/071638 WO2009018373A2 (fr) 2007-07-31 2008-07-30 Administration transdermique de (2s)-(4e)-n-méthyl-5-(3-(5-isopropoxypyridin)yl)-4-pentén-2-amine

Country Status (14)

Country Link
US (1) US20100247617A1 (fr)
EP (1) EP2182932A2 (fr)
JP (1) JP2010535237A (fr)
KR (1) KR20100052490A (fr)
CN (1) CN101772343A (fr)
AU (1) AU2008282205A1 (fr)
BR (1) BRPI0815070A2 (fr)
CA (1) CA2695214A1 (fr)
CO (1) CO6300839A2 (fr)
EC (1) ECSP109908A (fr)
NZ (1) NZ582826A (fr)
RU (1) RU2010107278A (fr)
WO (1) WO2009018373A2 (fr)
ZA (1) ZA201000721B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014012652A1 (fr) 2012-07-20 2014-01-23 Grünenthal GmbH Administration assistée par champ électrique de tapentadol

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232316B1 (en) * 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
WO2002005801A2 (fr) * 2000-07-14 2002-01-24 Targacept, Inc. Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
US20060024358A1 (en) * 2004-07-30 2006-02-02 Santini John T Jr Multi-reservoir device for transdermal drug delivery and sensing
US20060062838A1 (en) * 2004-09-13 2006-03-23 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
WO2008034041A2 (fr) * 2006-09-15 2008-03-20 Astrazeneca Ab Combinaisons thérapeutiques
WO2008091588A1 (fr) * 2007-01-22 2008-07-31 Targacept, Inc. Administration intranasale, buccale ou sublinguale d'analogues de métanicotine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192946A (en) * 1978-06-29 1980-03-11 Ciba-Geigy Corporation Process for producing 3-hydroxy-5-halopyridines
DE3148651A1 (de) * 1981-12-09 1983-07-21 Henkel Kgaa "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente"
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
JP4240815B2 (ja) * 1998-06-16 2009-03-18 ターガセプト，インコーポレイテッド アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用
US6337351B1 (en) * 1998-10-22 2002-01-08 Targacept, Inc. Pharmaceutical compositions and methods for use
US6506769B2 (en) * 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6432954B1 (en) * 2000-07-14 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232316B1 (en) * 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
WO2002005801A2 (fr) * 2000-07-14 2002-01-24 Targacept, Inc. Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
US20060024358A1 (en) * 2004-07-30 2006-02-02 Santini John T Jr Multi-reservoir device for transdermal drug delivery and sensing
US20060062838A1 (en) * 2004-09-13 2006-03-23 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
WO2008034041A2 (fr) * 2006-09-15 2008-03-20 Astrazeneca Ab Combinaisons thérapeutiques
WO2008091588A1 (fr) * 2007-01-22 2008-07-31 Targacept, Inc. Administration intranasale, buccale ou sublinguale d'analogues de métanicotine

Also Published As

Publication number Publication date
AU2008282205A1 (en) 2009-02-05
CN101772343A (zh) 2010-07-07
AU2008282205A8 (en) 2010-03-04
ZA201000721B (en) 2010-10-27
US20100247617A1 (en) 2010-09-30
BRPI0815070A2 (pt) 2018-07-31
JP2010535237A (ja) 2010-11-18
WO2009018373A3 (fr) 2009-03-26
KR20100052490A (ko) 2010-05-19
CO6300839A2 (es) 2011-07-21
RU2010107278A (ru) 2011-09-10
NZ582826A (en) 2011-10-28
ECSP109908A (es) 2010-05-31
CA2695214A1 (fr) 2009-02-05
EP2182932A2 (fr) 2010-05-12

Similar Documents

Publication Publication Date Title
EP2123274B1 (fr) Composition médicinale pour une absorption transdermique, unité de stockage de la composition médicinale et préparation par absorption transdermique utilisant celle-ci
US9642850B2 (en) Method of providing sustained analgesia with buprenorphine
KR101891186B1 (ko) 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물
JPWO2008108286A6 (ja) 経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤
KR101891185B1 (ko) 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
KR20160055934A (ko) 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
US8017146B2 (en) Transdermal delivery system with two superimposed adhesive layers having different affinities to the active substance comprised
US20070248657A1 (en) Multi-compartment transdermal pain control device
JP5345813B2 (ja) オキシコドン経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤
US20120077836A1 (en) Methods of administering (4ar,10ar)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo [g] quinoline-6,7-diol and related compounds across the oral mucosa, the nasal mucosa or the skin and pharmaceutical compositions thereof
US20100247617A1 (en) Transdermal Administration Of (2S)-(4E)-N-Methyl-5-(3-(5-Isopropoxypyridin)yl)-4-Penten-2-Amine
US20060223786A1 (en) Transdermal pain control method and device
EP0918521A1 (fr) Formulation pour le traitement et/ou la prophylaxie de la demence
AU721101C (en) Formulation for the treatment and/or prophylaxis of dementia
JP2010535237A5 (fr)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880101391.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08796889

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 203397

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/000900

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010010122

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2008282205

Country of ref document: AU

Ref document number: 10007021

Country of ref document: CO

Ref document number: 12010500188

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 582826

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2010520158

Country of ref document: JP

Ref document number: 2695214

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 973/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008796889

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008282205

Country of ref document: AU

Date of ref document: 20080730

Kind code of ref document: A

Ref document number: 20107004203

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010107278

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: PI 2010000456

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12671232

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0815070

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100201